Lunit announced a strategic collaboration with AstraZeneca (AZN) to develop AI-powered digital pathology solutions. The solution in focus is Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC
- FDA Cellular, Tissue & Gene Therapies Advisory Committee holds virtual meeting
- Soros boosts stake in AstraZeneca, exits Apple position
- AstraZeneca put volume heavy and directionally bearish
- Reporters tweets about ‘vague whispers’ of bid interest in TG Therapeutics